Personalized vaccine for recurrent ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a personalized cancer vaccine made from your own tumor cells. It is for women with advanced ovarian, fallopian tube, or primary peritoneal cancer that has returned after at least one round of platinum chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and female.
- You have advanced ovarian, primary peritoneal, or fallopian tube cancer (not carcinosarcoma) that has been treated with at least one round of platinum-based chemotherapy, and your doctor says a single drug is a good next step.
- Your cancer has come back or progressed after your most recent treatment.
- You have at least two spots of cancer that can be seen on scans, and you are willing to have a small piece of tumor (about 1 gram) removed for the vaccine.
- You are generally able to care for yourself (ECOG performance 0-2) and have recovered from side effects of prior treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized vaccine (NeoOVSV) made from your tumor’s unique markers (neoantigens). It’s for women with Stage II or III epithelial ovarian cancer who had successful surgery to remove all visible cancer. The goal is to see if the vaccine is safe and helps your immune system fight any remaining cancer cells.
This trial tests a new approach using your own immune cells (tumor-infiltrating lymphocytes) that have been modified to work better, followed by a combination of oral chemo and immunotherapy. It's for people with ovarian cancer that has come back after standard treatment.
This trial tests a combination treatment for advanced ovarian cancer that hasn't been treated before. It combines chemotherapy, a personalized vaccine made from your own immune cells, and a drug called pembrolizumab to help your immune system fight the cancer.
This study tests a personalized mRNA vaccine (NeoOVIV) for ovarian cancer patients who have already had surgery. The vaccine is designed to train your immune system to attack cancer cells that remain after surgery, based on unique markers in your tumor.
This Phase 1 study tests whether giving your own immune cells—engineered to target the FSH receptor—can control recurrent ovarian-related cancers. It’s mainly looking at safety and early signs of activity for patients whose cancer has not responded well to standard platinum chemotherapy.
This trial tests a vaccine called CryptiVax-1001 for people with advanced ovarian cancer who have finished first-line chemotherapy and are in remission, as maintenance therapy. The goal is to see if the vaccine can help keep the cancer from coming back.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.